601519 Disclosed is a pharmaceutical composition for treating hepatitis B virus infection in a human, comprising: a first active pharmaceutical ingredient consisting of more than 400 mg to about 1500 mg of lamivudine, (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, or a therapeutically equivalent amount of a pharmaceutically acceptable salt or ester thereof and a second active pharmaceutical ingredient consisting of about 1 mg to about 10 mg of adefovir dipivoxil, bis(pivaloyloxymethyl)(9-[(R)-2(phosphonomethoxy)ethyl] adenine, or a therapeutically equivalent amount of a pharmaceutically acceptable salt or ester thereof.
